	US 12,403,147 B2
	Treatment of ocular inflammation following ocular surgery
Thorsteinn Loftsson, Reykjavik (IS); and Zoltán Fülöp, Budapest (HU)
Assigned to Oculis Operations Sàrl, Lausanne (CH)
Filed by Oculis Operations Sàrl, Lausanne (CH)
Filed on Sep. 23, 2024, as Appl. No. 18/893,790.
Application 18/893,790 is a continuation of application No. 17/624,311, granted, now 12,097,209, previously published as PCT/EP2020/068398, filed on Jun. 30, 2020.
Claims priority of application No. 19183719 (EP), filed on Jul. 1, 2019; and application No. 20174202 (EP), filed on May 12, 2020.
Prior Publication US 2025/0009757 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/20 (2006.01); A61K 47/40 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01)

CPC A61K 31/573 (2013.01) [A61K 9/0048 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/20 (2013.01); A61K 47/40 (2013.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01)]

11 Claims

1. A method for the treatment of inflammation following an ocular surgery in a human subject in need thereof, comprising topically administering to an affected eye of the subject, a therapeutically efficient amount of an aqueous eye drop formulation comprising i) 1.5% weight to volume (w/v) of dexamethasone; ii) between 5% and 25% w/v of γ-cyclodextrin; and iii) between 0.1% and 0.5% w/v of sodium thiosulfate; wherein the aqueous eye drop formulation comprises a suspension comprising solid complexes of dexamethasone and γ-cyclodextrin, wherein the aqueous eye drop formulation is in a container made of plastic that allows oxidation of its contents; wherein the aqueous eye drop formulation has a pH of between 4.5 and 6, and wherein the eye drop formulation is administered at a dosage of one drop once or twice every day for two weeks starting the day after surgery.